Compare JPM & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JPM | AZN |
|---|---|---|
| Founded | 1799 | 1992 |
| Country | United States | United Kingdom |
| Employees | 320079 | 96100 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 837.0B | 316.4B |
| IPO Year | N/A | N/A |
| Metric | JPM | AZN |
|---|---|---|
| Price | $311.99 | $185.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 1 |
| Target Price | ★ $331.93 | N/A |
| AVG Volume (30 Days) | ★ 7.4M | 1.7M |
| Earning Date | 04-14-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.94% | 1.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.51 | $10.34 |
| Revenue Next Year | $4.11 | $6.43 |
| P/E Ratio | ★ $15.42 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $262.71 | $68.62 |
| 52 Week High | $337.25 | $212.71 |
| Indicator | JPM | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 59.15 | 49.81 |
| Support Level | $294.09 | $180.98 |
| Resistance Level | $315.32 | $191.50 |
| Average True Range (ATR) | 5.85 | 3.00 |
| MACD | 1.09 | -0.05 |
| Stochastic Oscillator | 84.95 | 61.27 |
JPMorgan is a leading global financial services firm with operations in 66 countries and over 318,000 employees as of year-end 2025. Under the JPMorgan brands, the bank holding company boasts a $4.9 trillion balance sheet and $2.68 trillion in deposits, as of March 2026. The firm generates its revenue across three core operating segments: consumer and community banking, the commercial and investment bank, and asset and wealth management. It maintains the top global ranking in investment banking fees with an 8.4% market share, serves millions of consumers through its network of over 5,000 US branches, and manages over $7.1 trillion in client assets within its wealth and asset management franchise.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.